SEARCH

SEARCH BY CITATION

References

  • Adermark L, Talani G, Lovinger DM (2009). Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity. Eur J Neurosci 29: 3241.
  • Alvarez-Fischer D, Henze C, Strenzke C, Westrich J, Ferger B, Höglinger GU et al. (2008). Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol 210: 182193.
  • Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V et al. (2010). The plant Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160: 677687.
  • Buckley NE (2008). The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 153: 309318.
  • Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC et al. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB2 receptor. Eur J Pharmacol 396: 141149.
  • Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM (2000). Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J 14: 14321438.
  • Fernández-Espejo E, Caraballo I, Rodriguez de Fonseca F, Ferrer B, El Banoua F, Flores JA et al. (2004). Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology 29: 11341142.
  • Fernández-Espejo E, Caraballo I, Rodríguez de Fonseca F, El Banoua F, Ferrer B, Flores JA et al. (2005). Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis 18: 591601.
  • Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A (2003). Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18: 16071614.
  • García-Arencibia M, González S, de Lago E, Ramos JA, Mechoulam R, Fernández-Ruiz J (2007). Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res 1134: 162170.
  • García-Arencibia M, Ferraro L, Tanganelli S, Fernández-Ruiz J (2008). Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett 438: 1013.
  • García-Arencibia M, García C, Fernández-Ruiz J (2009). Cannabinoids and Parkinson's disease. CNS Neurol Disord Drug Targets 8: 432439.
  • González S, Scorticati C, García-Arencibia M, de Miguel R, Ramos JA, Fernández-Ruiz J (2006). Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. Brain Res 1073–1074: 209219.
  • Gubellini P, Picconi B, Bari M, Battista N, Calabresi P, Centonze D et al. (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Neurosci 22: 69006907.
  • Hunter RL, Cheng B, Choi DY, Liu M, Liu S, Cass WA et al. (2009). Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice. J Neurosci Res 87: 19131921.
  • Jiménez-Del-Rio M, Daza-Restrepo A, Velez-Pardo C (2008). The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat: implications in Parkinson's disease. Neurosci Res 61: 404411.
  • Kelsey JE, Harris O, Cassin J (2009). The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav Brain Res 203: 304307.
  • Lastres-Becker I, Cebeira M, de Ceballos M, Zeng B-Y, Jenner P, Ramos JA et al. (2001). Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci 14: 18271832.
  • Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J (2005). Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19: 96107.
  • Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265275.
  • Mailleux P, Vanderhaeghen JJ (1993). Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem 61: 17051712.
  • Maneuf YP, Nash JE, Crossman AR, Brotchie JM (1996). Activation of the cannabinoid receptor by Δ9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. Eur J Pharmacol 308: 161164.
  • Mesnage V, Houeto JL, Bonnet AM, Clavier I, Arnulf I, Cattelin F et al. (2004). Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson's disease. Clin Neuropharmacol 27: 108110.
  • Nagatsu T, Sawada M (2007). Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. J Neural Transm Suppl 72: 113120.
  • Ossowska K, Konieczny J, Wardas J, Pietraszek M, Kuter K, Wolfarth S et al. (2007). An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 32: 179188.
  • Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: London.
  • Pérez-Rial S, García-Gutiérrez MS, Molina JA, Pérez-Nievas BG, Ledent C, Leiva C et al. (2010). Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiol Aging 32: 631645.
  • Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH et al. (2007). The psychoactive plant cannabinoid, Δ9-tetrahydrocannabinol, is antagonized by Δ8- and Δ9-tetrahydrocannabivarin in mice in vivo. Br J Pharmacol 150: 586594.
  • Pezzoli G, Zini M (2010). Levodopa in Parkinson's disease: from the past to the future. Expert Opin Pharmacother 11: 627635.
  • Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A et al. (2005). High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol 57: 777779.
  • Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernández E et al. (2009). WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci 29: 21772186.
  • Rodriguez Diaz M, Abdala P, Barroso-Chinea P, Obeso J, González-Hernández T (2001). Motor behavioural changes after intracerebroventricular injection of 6-hydroxydopamine in the rat: an animal model of Parkinson's disease. Behav Brain Res 122: 7992.
  • Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernández-Ruiz J et al. (2000). Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci 66: 485494.
  • Sañudo-Peña MC, Tsou K, Walker JM (1999). Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sci 65: 703713.
  • Segovia G, Mora F, Crossman AR, Brotchie JM (2003). Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov Disord 18: 138149.
  • Thomas B, Beal MF (2007). Parkinson's disease. Hum Mol Genet 16: R183R194.
  • Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA et al. (2005). Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917926.